(3S,5S,6S)-5-[(2R,3R,4S,5S)-3,4-Bis-(tert-butyl-dimethyl-silanyloxy)-5-(tert-butyl-dimethyl-silanyloxymethyl)-tetrahydro-furan-2-yloxy]-3-(tert-butyl-dimethyl-silanyloxy)-6-methyl-octanoic acid | 850004-28-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (3S,5S,6S)-5-[(2R,3R,4S,5S)-3,4-Bis-(tert-butyl-dimethyl-silanyloxy)-5-(tert-butyl-dimethyl-silanyloxymethyl)-tetrahydro-furan-2-yloxy]-3-(tert-butyl-dimethyl-silanyloxy)-6-methyl-octanoic acid
• 英文别名: (3S,5S,6S)-5-[(2R,3R,4S,5S)-3,4-bis[[tert-butyl(dimethyl)silyl]oxy]-5-[[tert-butyl(dimethyl)silyl]oxymethyl]oxolan-2-yl]oxy-3-[tert-butyl(dimethyl)silyl]oxy-6-methyloctanoic acid
• CAS: 850004-28-3
• 化学式: C₃₈H₈₂O₈Si₄
• 分子量: 779.406
• InChiKey: DWOQSMPARLVXSG-UJDQTLLPSA-N

物化性质

• 沸点：
  656.8±55.0 °C(Predicted)
• 密度：
  0.96±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  11.2
• 重原子数：
  50
• 可旋转键数：
  21
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.97
• 拓扑面积：
  92.7
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  (3S,5S,6S)-5-[(2R,3R,4S,5S)-3,4-Bis-(tert-butyl-dimethyl-silanyloxy)-5-(tert-butyl-dimethyl-silanyloxymethyl)-tetrahydro-furan-2-yloxy]-3-(tert-butyl-dimethyl-silanyloxy)-6-methyl-octanoic acid 在 palladium on activated charcoal 4-二甲氨基吡啶 、 ruthenium trichloride 、 sodium periodate 、 氢气 、 三乙胺 作用下， 以 甲醇 、 四氯化碳 、 水 、 甲苯 、 乙腈 为溶剂， 反应 5.33h， 生成 (3S,5S,6S)-5-[(3S,5S,6S)-5-[(2R,3R,4S,5S)-3,4-bis[[tert-butyl(dimethyl)silyl]oxy]-5-[[tert-butyl(dimethyl)silyl]oxymethyl]oxolan-2-yl]oxy-3-[tert-butyl(dimethyl)silyl]oxy-6-methyloctanoyl]oxy-3-[tert-butyl(dimethyl)silyl]oxy-6-methyloctanoic acid
  参考文献：
  名称：

  Synthetic Studies of Complex Immunostimulants from Quillaja saponaria:  Synthesis of the Potent Clinical Immunoadjuvant QS-21A_api

  摘要：

  QS-21 is one of the most promising new adjuvants for immune response potentiation and dose-sparing in vaccine therapy given its exceedingly high level of potency and its favorable toxicity profile. Melanoma, breast cancer, small cell lung cancer, prostate cancer, HIV-1, and malaria are among the numerous maladies targeted in more than 80 recent and ongoing vaccine therapy clinical trials involving QS-21 as a critical adjuvant component for immune response augmentation. QS-21 is a natural product immunostimulatory adjuvant, eliciting both T-cell- and antibody-mediated immune responses with microgram doses. Herein is reported the synthesis of QS-21A(api) in a highly modular strategy, applying novel glycosylation methodologies to a convergent construction of the potent saponin immunostimulant. The chemical synthesis of QS-21 offers unique opportunities to probe its mode of biological action through the preparation of otherwise unattainable nonnatural saponin analogues.

  DOI：

  10.1021/ja062364i
• 作为产物：
  描述：

  (R)-(+)-5-(benzyloxy)-3-(tert-butyldimethylsilyloxy)pentanal 在 palladium on activated charcoal ruthenium trichloride 、 sodium periodate 、 正丁基锂 、 potassium tert-butylate 、 氢气 作用下， 以 四氢呋喃 、 甲醇 、 四氯化碳 、 二氯甲烷 、 水 、 甲苯 、 乙腈 、 Petroleum ether 为溶剂， 反应 32.8h， 生成 (3S,5S,6S)-5-[(2R,3R,4S,5S)-3,4-Bis-(tert-butyl-dimethyl-silanyloxy)-5-(tert-butyl-dimethyl-silanyloxymethyl)-tetrahydro-furan-2-yloxy]-3-(tert-butyl-dimethyl-silanyloxy)-6-methyl-octanoic acid
  参考文献：
  名称：

  Synthetic Studies of Complex Immunostimulants from Quillaja saponaria:  Synthesis of the Potent Clinical Immunoadjuvant QS-21A_api

  摘要：

  QS-21 is one of the most promising new adjuvants for immune response potentiation and dose-sparing in vaccine therapy given its exceedingly high level of potency and its favorable toxicity profile. Melanoma, breast cancer, small cell lung cancer, prostate cancer, HIV-1, and malaria are among the numerous maladies targeted in more than 80 recent and ongoing vaccine therapy clinical trials involving QS-21 as a critical adjuvant component for immune response augmentation. QS-21 is a natural product immunostimulatory adjuvant, eliciting both T-cell- and antibody-mediated immune responses with microgram doses. Herein is reported the synthesis of QS-21A(api) in a highly modular strategy, applying novel glycosylation methodologies to a convergent construction of the potent saponin immunostimulant. The chemical synthesis of QS-21 offers unique opportunities to probe its mode of biological action through the preparation of otherwise unattainable nonnatural saponin analogues.

  DOI：

  10.1021/ja062364i

文献信息

• [EN] TRITERPENE SAPONIN SYNTHESIS, INTERMEDIATES AND ADJUVANT COMBINATIONS<br/>[FR] SYNTHÈSE DE SAPONINE TRITERPÉNIQUE, INTERMÉDIAIRES ET COMBINAISONS D'ADJUVANTS
  申请人：ADJUVANCE TECH INC

  公开号：WO2018191598A1

  公开（公告）日：2018-10-18

  The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.

  本申请涉及三萜甙苷皂苷衍生的佐剂、其合成以及中间体。该申请还提供了包含本发明化合物的药物组合物，以及使用这些化合物或组合物在治疗和免疫传染病方面的方法。
• Design and Synthesis of Potent <i>Quillaja</i> Saponin Vaccine Adjuvants
  作者：Michelle M. Adams、Payal Damani、Nicholas R. Perl、Annie Won、Feng Hong、Philip O. Livingston、Govind Ragupathi、David Y. Gin

  DOI：10.1021/ja9082842

  日期：2010.2.17

  promise of QS-21 adjuvant is curtailed by several factors, including its scarcity, difficulty in purification to homogeneity, dose-limiting toxicity, and chemical instability. Here, we report the design, synthesis, and evaluation of chemically stable synthetic saponins. These novel, amide-modified, non-natural substances exhibit immunopotentiating effects in vivo that rival or exceed that of QS-21 in evaluations

  抗肿瘤和抗病毒疫苗的成功通常需要使用佐剂，这种物质可显着增强对共同施用抗原的免疫反应。只有少数佐剂具有足够的效力和可接受的临床研究毒性。QS-21 是一种很有前景的佐剂，它是一种皂苷天然产物，是许多癌症和传染病疫苗临床试验的首选免疫增强剂。然而，QS-21 佐剂的治疗前景受到多种因素的限制，包括其稀缺性、难以纯化至均质、剂量限制性毒性和化学不稳定性。在这里，我们报告了化学稳定的合成皂苷的设计、合成和评估。这些新颖的、酰胺改性的、在 GD3-KLH 黑色素瘤结合疫苗的评估中，非天然物质在体内表现出与 QS-21 相媲美或超过 QS-21 的免疫增强作用。这些新型皂苷的高度收敛合成制剂为发现用于专门定制疫苗疗法的改进分子佐剂开辟了新途径。
• Synthesis of the Potent Immunostimulatory Adjuvant QS-21A
  作者：Pengfei Wang、Yong-Jae Kim、Mauricio Navarro-Villalobos、Bridget D. Rohde、David Y. Gin

  DOI：10.1021/ja0422007

  日期：2005.3.1

  QS-21A is one of the most promising new adjuvants for immune response potentiation and dose-sparing in vaccine therapy, given its exceedingly high level of potency and its favorable toxicity profile. Melanoma, breast cancer, small cell lung cancer, prostate cancer, HIV-1, and malaria are among the numerous maladies targeted in more than 80 recent and ongoing clinical trials involving QS-21A as a critical component for immune response augmentation in microgram doses. Herein is reported the first synthesis and structure verification of QS-21Aapi, applying novel glycosylation methodologies in the convergent modular construction of this rare and potent natural product immunostimulant.